Vahabi Anaraki Parichehr, Aminorroaya Ashraf, Amini Massoud, Momeni Fatemeh, Feizi Awat, Iraj Bijan, Tabatabaei Azamosadat
Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Med Sci. 2017 Sep 26;22:103. doi: 10.4103/jrms.JRMS_1048_16. eCollection 2017.
The link between autoimmune thyroid diseases and Vitamin D deficiency has been reported. However, there are controversies in this regard. We conducted a double-blind randomized placebo-controlled clinical trial to investigate the effect of Vitamin D deficiency treatment on thyroid function and autoimmunity marker (thyroid peroxidase antibody [TPO-Ab]) in patients with Hashimoto's thyroiditis.
Fifty-six patients with Hashimoto's thyroiditis and Vitamin D deficiency (25-hydroxyvitamin D level ≤20 ng/mL) were randomly allocated into two groups to receive Vitamin D (50000 IU/week, orally) or placebo for 12 weeks, as Vitamin D-treated ( = 30) and control ( = 26) groups, respectively. TPO-Ab, thyroid-stimulating hormone (TSH), parathormone, calcium, albumin, and creatinine concentrations were compared before and after trial between and within groups. The data were presented as mean (standard error [SE]) and analyzed by appropriate tests.
Mean (SE) of Vitamin D was increased in Vitamin D-treated group (45.5 [1.8] ng/mL vs. 12.7 [0.7] ng/mL, = 0.01). Mean (SE) of TPO-Ab did not significantly change in both groups (734 [102.93] IU/mL vs. 820.25 [98.92] IU/mL, = 0.14 in Vitamin D-treated and 750.03 [108.7] [IU/mL] vs. 838.07 [99.4] [IU/mL] in placebo-treated group, = 0.15). Mean (SE) of TSH was not changed in both groups after trial, = 0.4 and = 0.15 for Vitamin D-treated and control groups, respectively. No significant difference was observed between two study groups in none studied variables ( > 0.05).
Vitamin D treatment in Vitamin D deficient patients with Hashimoto's thyroiditis could not have significant effect on thyroid function and autoimmunity.
自身免疫性甲状腺疾病与维生素D缺乏之间的关联已有报道。然而，这方面存在争议。我们进行了一项双盲随机安慰剂对照临床试验，以研究维生素D缺乏治疗对桥本甲状腺炎患者甲状腺功能和自身免疫标志物（甲状腺过氧化物酶抗体 [TPO-Ab]）的影响。
56例患有桥本甲状腺炎且维生素D缺乏（25-羟维生素D水平≤20 ng/mL）的患者被随机分为两组，分别接受维生素D（50000 IU/周，口服）或安慰剂治疗12周，即维生素D治疗组（n = 30）和对照组（n = 26）。比较两组组间及组内试验前后的TPO-Ab、促甲状腺激素（TSH）、甲状旁腺激素、钙、白蛋白和肌酐浓度。数据以均值（标准误 [SE]）表示，并通过适当的检验进行分析。
维生素D治疗组的维生素D均值（SE）升高（45.5 [1.8] ng/mL 对 12.7 [0.7] ng/mL，P = 0.01）。两组的TPO-Ab均值（SE）均无显著变化（维生素D治疗组为734 [102.93] IU/mL 对 820.25 [98.92] IU/mL，P = 0.14；安慰剂治疗组为750.03 [108.7] [IU/mL] 对 838.07 [99.4] [IU/mL]，P = 0.15）。试验后两组的TSH均值均未改变，维生素D治疗组和对照组的P分别为0.4和0.15。在所有研究变量中，两个研究组之间均未观察到显著差异（P > 0.05）。
维生素D缺乏的桥本甲状腺炎患者接受维生素D治疗对甲状腺功能和自身免疫无显著影响。
